Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.55 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.52 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032956 | 0.93 | PTGIR (0.62) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL17186490 | 0.91 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL4035161 | 0.91 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL10800812 | 0.91 | PTGIR (0.83) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL3169468 | 0.91 | PTGIR (0.60) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| Hydrochloric Acid SCHEMBL18605409 | 0.90 | PTGIR (0.59) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL14599597 | 0.87 | PTGIR (0.57) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL28904914 | 0.87 | PTGIR (0.64) | PTGIRADRA2AADRA2BADRA2CWDR5 | |
| SCHEMBL7430405 | 0.84 | MLLT1 (0.56) | PTGIRADRA2AADRA2BADRA2CMLLT1 | |
| SCHEMBL8152769 | 0.84 | WDR5 (0.69) | PTGIRWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190322633-A1 | STROMAL DERIVED FACTOR INHIBITION AND CXCR4 BLOCKADE | BLAINE, THEODORE A. | 2019-10-24 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012112919-A1 | STROMAL DERIVED FACTOR INHIBITION AND CXCR4 BLOCKADE | RHODE ISLAND HOSTPITAL (US) | 2012-08-23 | — | — | WO | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | PTGIR 375/4885ADRA2A 1357/4885ADRA2B 1563/4885 |
| US-20190322633-A1 | STROMAL DERIVED FACTOR INHIBITION AND CXCR4 BLOCKADE | CXCL12, CXCR4, SDF4 | PTGIR 611/4885ADRA2A 505/4885ADRA2B 316/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | PTGIR 375/4885ADRA2A 1357/4885ADRA2B 1563/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | PTGIR 170/4885ADRA2A 628/4885ADRA2B 746/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | PTGIR 375/4885ADRA2A 1357/4885ADRA2B 1563/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | PTGIR 375/4885ADRA2A 1357/4885ADRA2B 1563/4885 |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | CXCR4, CXCL12, CXCR1 | PTGIR 170/4885ADRA2A 628/4885ADRA2B 746/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | PTGIR 375/4885ADRA2A 1357/4885ADRA2B 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.